Report says inclusivity and diversity vital for UK clinical trials 4 Apr 2023
The recently published ‘Advancing Clinical Trials’ report puts forward equality, diversity and inclusion (EDI) in clinical trials as central to the future of in the UK’s life sciences industry. Based on a roundtable held by MedCity, the Faculty of Pharmaceutical Medicine and Imperial College Healthcare NHS Trust, the document suggests that, if the UK wants to become a global leader in the sector, a focus on EDI could support this aim.
While the UK’s life sciences sector has long been recognised as a strength and is supported by the government, the number of clinical trials started here has declined sharply since 2017. This and the reduction in investment from pharma companies are threatening the sector’s future and hence patients’ access to treatments. By making EDI central to clinical trials, the report states that the UK can set itself apart from its competitors.
Read the full report via this link.